Cost-effectiveness analysis of axitinib through a probabilistic decision model
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness analysis of axitinib through a probabilistic decision model
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 16, Issue 8, Pages 1233-1243
Publisher
Informa Healthcare
Online
2015-05-09
DOI
10.1517/14656566.2015.1039982
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation
- (2014) J Thompson Coon et al. HEALTH TECHNOLOGY ASSESSMENT
- Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
- (2013) D Cella et al. BRITISH JOURNAL OF CANCER
- Axitinib for the treatment of advanced renal cell carcinoma
- (2013) Hideyuki Akaza et al. EXPERT OPINION ON PHARMACOTHERAPY
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- A Cost-Effectiveness Analysis of Axitinib and Sorafenib for 2nd Line Treatment of Advanced Renal Cell Carcinoma After Failure of Cytokines in the United States
- (2013) I.O. Stillman et al. VALUE IN HEALTH
- Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer?
- (2011) Eitan Amir et al. EUROPEAN JOURNAL OF CANCER
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Delivering affordable cancer care in high-income countries
- (2011) Richard Sullivan et al. LANCET ONCOLOGY
- Drugs for Rare Diseases: Influence of Orphan Designation Status on Price
- (2011) Eline Picavet et al. Applied Health Economics and Health Policy
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Epidemiology and risk factors for kidney cancer
- (2010) Wong-Ho Chow et al. Nature Reviews Urology
- Family History and Risk of Renal Cell Carcinoma: Results from a Case-Control Study and Systematic Meta-Analysis
- (2009) J. Clague et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
- (2009) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Renal cell carcinoma
- (2009) Brian I Rini et al. LANCET
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
- Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland
- (2008) Timo Purmonen et al. CLINICAL THERAPEUTICS
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expected Value of Perfect Information: An Empirical Example of Reducing Decision Uncertainty by Conducting Additional Research
- (2008) Jan B. Oostenbrink et al. VALUE IN HEALTH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More